Ahmad Younis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ahmad Younis has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Karam Albdour
University of Jordan
2 shared publications - Omar Ismail
School of Medicine, University of Jordan, Amman, Jordan
2 shared publications - Ahmad Turk
The Advanced Heart Diseases Center
1 shared publication - Amin Alsaras
The University of Jordan
1 shared publication - Kamel Jaber
The University of Jordan
1 shared publication - Nour H. Mash’aL
Faculty of Medicine University of Jordan Amman Jordan
1 shared publication
Latest Publications
- 9 December 2025
- Published by Taylor & Francis in Hospital Practice
- Vol. 53 (1) , 2600245
The efficacy of melatonin as a preoperative anxiolytic in real-world setting: a randomized controlled trial
Preoperative anxiety is linked to various adverse effects on anesthesia, intraoperative vital signs, and postoperative outcomes. Despite its widespread impact, managing preoperative anxiety is not consistently implemented, partly due to concerns over the efficacy and side effects of anxiolytic drugs. Previous clinical trials on the anxiolytic effect of melatonin showed conflicting results regarding its effect. Furthermore, they involved placing the patients in settings that deviate of real-world clinical practice. We sought to assess the efficacy of melatonin as a preoperative anxiolytic in real-world settings. This is a triple-blinded, randomized, controlled clinical trial that enrolled 87 patients aged 18 to 65 planned for elective surgery under general anesthesia. They were divided into three groups to receive melatonin, diazepam, or a placebo and were placed in the same waiting rooms as other non-enrolled patients. Preoperative anxiety was assessed at baseline and one-hour post-treatment using the Visual Analog Scale (VAS) and Amsterdam Preoperative Anxiety and Information Scale (APAIS). Secondary outcomes included changes in orientation and sedation levels. Of the 87 enrolled participants, 76 completed the second assessment. The median age of the participants was 38 years (IQR = 18.5), and 50.6% were females. our study showed no significant effect of melatonin on preoperative anxiety, sedation, or orientation compared to diazepam or placebo. Our study highlights the need for incorporating other factors in future clinical trials on preoperative anxiety to better translate the results into a real-world setting. NCT06103188.
- 9 December 2025
- Published by Taylor & Francis in Hospital Practice
- Vol. 53 (1) , 2600245
The efficacy of melatonin as a preoperative anxiolytic in real-world setting: a randomized controlled trial
Preoperative anxiety is linked to various adverse effects on anesthesia, intraoperative vital signs, and postoperative outcomes. Despite its widespread impact, managing preoperative anxiety is not consistently implemented, partly due to concerns over the efficacy and side effects of anxiolytic drugs. Previous clinical trials on the anxiolytic effect of melatonin showed conflicting results regarding its effect. Furthermore, they involved placing the patients in settings that deviate of real-world clinical practice. We sought to assess the efficacy of melatonin as a preoperative anxiolytic in real-world settings. This is a triple-blinded, randomized, controlled clinical trial that enrolled 87 patients aged 18 to 65 planned for elective surgery under general anesthesia. They were divided into three groups to receive melatonin, diazepam, or a placebo and were placed in the same waiting rooms as other non-enrolled patients. Preoperative anxiety was assessed at baseline and one-hour post-treatment using the Visual Analog Scale (VAS) and Amsterdam Preoperative Anxiety and Information Scale (APAIS). Secondary outcomes included changes in orientation and sedation levels. Of the 87 enrolled participants, 76 completed the second assessment. The median age of the participants was 38 years (IQR = 18.5), and 50.6% were females. our study showed no significant effect of melatonin on preoperative anxiety, sedation, or orientation compared to diazepam or placebo. Our study highlights the need for incorporating other factors in future clinical trials on preoperative anxiety to better translate the results into a real-world setting. NCT06103188.
- 1 April 2025
- Published by SAGE Publications in JRSM Cardiovascular Disease
- Vol. 14
Pro-adrenomedullin as a prognostic biomarker in patients with heart failure: A systematic review and meta-analysis
Pro-adrenomedullin (proADM) involved in cardiovascular hemostasis, has shown promise as a prognostic biomarker in heart failure (HF). However, it's precise role in predicting HF outcomes has yet to be defined. We conducted a systematic review and meta-analysis to determine whether proADM can effectively predict outcomes in patients with HF. We systemtically searched Pubmed, Cochrane, Web of Science, and Scopus for studies on proADM levels in adults (≥18 years) diagnosed with HF. Cohort studies, case-control studies, and randomized controlled trials were considered. The primary outcomes were mortality and hospitalization, with the risk of bias assessed using the QUIPs tool. A random effects meta-analysis was conducted to report pooled hazard ratio (HR) and 95% confidence intervals. Our search identified 956 studies, of which 25 met the inclusion criteria after full-text screening, encompassing a total of 13,915 patients. ProADM emerged as a robust predictor of mortality (HR = 2.46, 95% CI [2.02–3.01]) and combined mortality/hospitalization (HR = 2.96, 95% CI [2.17–4.04]). Notably, each 1-log-unit (nmol/L) increase in proADM was associated with a 196% higher risk of mortality or hospitalization and a 146% higher risk of mortality. ProADM shows significant potential as a prognostic biomarker for HF, with elevated levels linked to a higher risk of mortality and hospitalization. Future research should focus on integrating proADM into risk assessment tools for predicting worsening HF events, as this could influence management guidelines and reshape our approach to treating HF patients.
- 1 April 2025
- Published by SAGE Publications in JRSM Cardiovascular Disease
- Vol. 14
Pro-adrenomedullin as a prognostic biomarker in patients with heart failure: A systematic review and meta-analysis
Pro-adrenomedullin (proADM) involved in cardiovascular hemostasis, has shown promise as a prognostic biomarker in heart failure (HF). However, it's precise role in predicting HF outcomes has yet to be defined. We conducted a systematic review and meta-analysis to determine whether proADM can effectively predict outcomes in patients with HF. We systemtically searched Pubmed, Cochrane, Web of Science, and Scopus for studies on proADM levels in adults (≥18 years) diagnosed with HF. Cohort studies, case-control studies, and randomized controlled trials were considered. The primary outcomes were mortality and hospitalization, with the risk of bias assessed using the QUIPs tool. A random effects meta-analysis was conducted to report pooled hazard ratio (HR) and 95% confidence intervals. Our search identified 956 studies, of which 25 met the inclusion criteria after full-text screening, encompassing a total of 13,915 patients. ProADM emerged as a robust predictor of mortality (HR = 2.46, 95% CI [2.02–3.01]) and combined mortality/hospitalization (HR = 2.96, 95% CI [2.17–4.04]). Notably, each 1-log-unit (nmol/L) increase in proADM was associated with a 196% higher risk of mortality or hospitalization and a 146% higher risk of mortality. ProADM shows significant potential as a prognostic biomarker for HF, with elevated levels linked to a higher risk of mortality and hospitalization. Future research should focus on integrating proADM into risk assessment tools for predicting worsening HF events, as this could influence management guidelines and reshape our approach to treating HF patients.